Journal
ARCHIVES OF PHARMACAL RESEARCH
Volume 42, Issue 7, Pages 549-559Publisher
PHARMACEUTICAL SOC KOREA
DOI: 10.1007/s12272-019-01146-9
Keywords
Th17 cells; IL-17; Oncogene; Inflammation; Immunotherapy; Cancer
Categories
Funding
- Cancer Prevention and Research Institute of Texas [RP130078]
- Department of Defense [W81XWH-16-1-0100]
- University of Texas MD Anderson Cancer Center, Center for Inflammation and Cancer Support Grant
Ask authors/readers for more resources
Th17 cells are a specialized subset of CD4+ T cells that are essential in driving inflammation during autoimmune disease and infection through a signature cytokine IL-17. Th17 cells have been found in various human cancers. The function of these cells in cancers is highly context-dependent; both tumor-promoting and tumor-suppressing activity have been reported. IL-17 and IL-22, Th17-derived cytokines, influence the tumor microenvironment by directly promoting transformed cell properties and neighboring stromal cell activity. These cytokines are also involved in regulation of the immune system by modulating the activities of myeloid cells and T cells. These findings suggest that Th17 cells and their cytokines are a key mediator of cancer development, representing a potential target for cancer therapy. Herein, I review recent preclinical studies on the function of Th17 cells and IL-17 in cancer and discuss possible therapeutic approaches to harness Th17 cells for cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available